HYDERABAD: Bharat Biotech International Ltd and UK-based pharmaceutical major GSK have announced plans to reduce the price of the world’s first malaria vaccine, RTS,S (branded as Mosquirix), to under $5 per dose by 2028. The move is part of their commitment to Gavi’s 2026–2030 funding cycle.
In a joint statement, the companies said the price cut—more than a 50% reduction—will be achieved through advancements in manufacturing processes, increased production capacity, cost efficiencies, and a low-profit pricing model aimed at improving global access.
